The activity of post-marketing surveillance results in a collection of large amount of data. The analysis of data is very useful for raising early warnings on possible adverse reactions of drugs. Association rule mining techniques have been heavily explored by the research community for identifying binary association between drugs and their adverse effects. But these techniques perform poorly and miss out several interesting associations when it comes to analysis of multidimensional data which may include multiple patient attributes, drugs and adverse drug reactions. In the present work, a clustering-based hybrid approach has been presented for finding quantitative multidimensional association from the large amount of data. Firstly, it employs clustering technique for segmentation of data into semantically coherent clusters. Furthermore, disproportionality method called proportional reporting ratio is applied on clustered data for generating statistically strong associations. The performance of the proposed methodology has been examined on the data taken from the U.S. Food and Drug Administration Adverse Event Reporting System database corresponding to Aspirin and nine other drugs which are prescribed along with Aspirin. The experimental results show that the proposed approach discovered a number of association rules which are very comprehensive and informative regarding relationship of patient traits and drugs with adverse drug reactions. On comparing experimental results with LPMiner, it is observed that the quantitative association rules discovered by LPMiner are just 8.3% of what have been discovered by the proposed methodology.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12539-020-00365-9DOI Listing

Publication Analysis

Top Keywords

drugs adverse
16
adverse drug
12
drug reactions
12
clustering-based hybrid
8
hybrid approach
8
quantitative multidimensional
8
patient attributes
8
attributes drugs
8
large amount
8
amount data
8

Similar Publications

Addressing the Environmental Impact of Pharmaceuticals: A Call to Action.

Br J Hosp Med (Lond)

January 2025

Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK.

The contribution of health care to environmental and climate crises is significant, under-addressed, and with consequences for human health. This editorial is a call to action. Focusing on pharmaceuticals as a major environmental threat, we examine pharmaceutical impacts across their lifecycle, summarising greenhouse gas emissions, pollution, and biodiversity loss, and outlining challenges and opportunities to reduce this impact.

View Article and Find Full Text PDF

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are emerging as an important class of drugs in the management of Type 2 Diabetes Mellitus (T2DM) and obesity. There are rising concerns of pulmonary aspiration with these medications due to drug-induced gastroparesis. While definitive association is uncertain, it is essential to be prudent and manage these patients as per the current evidence and recommendations.

View Article and Find Full Text PDF

Evolution of Alzheimer's Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy.

Pharmaceutics

January 2025

Laboratorio Experimental de Enfermedades Neurodegenerativas, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 14269, Mexico.

Alzheimer's disease (AD) represents an escalating global health crisis, constituting the leading cause of dementia among the elderly and profoundly impairing their quality of life. Current FDA-approved drugs, such as rivastigmine, donepezil, galantamine, and memantine, offer only modest symptomatic relief and are frequently associated with significant adverse effects. Faced with this challenge and in line with advances in the understanding of the pathophysiology of this neurodegenerative condition, various innovative therapeutic strategies have been explored.

View Article and Find Full Text PDF

Sorafenib-Loaded Silica-Containing Redox Nanoparticle Decreases Tumorigenic Potential of Lewis Lung Carcinoma.

Pharmaceutics

January 2025

Department of Materials Science, Graduate School of Pure and Applied Sciences, University of Tsukuba, Tennoudai 1-1-1, Tsukuba 305-8573, Ibaraki, Japan.

Orally administered sorafenib has shown limited improvement in overall survival for non-small-cell lung cancer patients, likely due to poor pharmacokinetics and adverse effects, including gastrointestinal toxicity. To address these issues, we developed silica-containing antioxidant nanoparticles (siRNP) as a carrier to enhance the therapeutic efficacy of lipophilic sorafenib. Sorafenib was loaded into siRNP via dialysis (sora@siRNP).

View Article and Find Full Text PDF

Highly active antiretroviral therapy has led to a significant increase in the life expectancy of people living with HIV. The trade-off is that HIV-infected patients often suffer from comorbidities that require additional treatment, increasing the risk of Drug-Drug Interactions (DDIs), the clinical relevance of which has often not been determined during registration trials of the drugs involved. Therefore, it is important to identify potential clinically relevant DDIs in order to establish the most appropriate therapeutic approaches.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!